Literature DB >> 30122648

Assessment of one-dose mumps-containing vaccine effectiveness on wild-type genotype F mumps viruses circulating in mainland China.

Aili Cui1, Zhen Zhu1, Naiying Mao1, Yuan Si2, Yu Ma2, Ying Hu3, Xiuying Deng3, Liping Wang4, Lingjia Zeng4, Yan Zhang5, Wenbo Xu6.   

Abstract

To clarify the protective effect of one-dose mumps-containing vaccines (MuCV) in mainland China, the antigenic variations of HN gene and cross-neutralization capacities between MuCV and wild type genotype F MuVs were studied. In total, 70 HN gene sequences of genotype F MuV representative strains obtained from 2001 to 2015, two types of MuCV strains, 139 pairs of pre- and post-vaccination serum samples from infants receiving one dose of MuCV vaccination were analyzed. Genotype-specific amino acid variations were observed in the potential antigenic epitopes between MuCV and wild-type genotype F MuVs circulating in mainland China. The mumps neutralization antibody titers induced by one-dose MuCV were found to be generally low. Moreover, significant differences in neutralization titers were observed between vaccine and wild-type strains. It could be concluded that one-dose MuCV had a cross-protective effect against the wild-type genotype F MuVs, but its effectiveness was limited, which might be caused by insufficient doses of MuCV vaccination and the genotype-specific antigenic differences between vaccine and wild-type MuVs as well. In addition, a poor linear correlation between mumps-specific IgG concentrations and neutralization titers was observed in this study, indicating the concentration of MuV-specific IgG could not fully reflect the neutralizing antibody titer in serum. Therefore, it is highly recommended to provide a second dose of MuCV to preschool children to increase MuV neutralizing antibody titers and use MuV cross-neutralization test as preferred tool for assessment of mumps-containing vaccine effectiveness on wild-type MuVs. This is the first report to assess the effectiveness of one-dose Chinese MuCV against wild-type genotype F MuVs, which would be benefit for the development of mumps vaccination strategy.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Antigenic variation; Cross-neutralization; Mumps virus; Mumps-containing vaccine effectiveness

Mesh:

Substances:

Year:  2018        PMID: 30122648     DOI: 10.1016/j.vaccine.2018.08.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Outbreak of mumps in a student population with high vaccination coverage in China: time for two-dose vaccination.

Authors:  Wei Qin; Yao Wang; Tao Yang; Xiao-Kang Xu; Xiang-Mei Meng; Chang-Jun Zhao; Shao-Yi Li; Shao-Yu Xie; Kai-Chun Li; Hong Su
Journal:  Hum Vaccin Immunother       Date:  2019-03-15       Impact factor: 3.452

Review 2.  Exploring the Mumps Virus Glycoproteins: A Review.

Authors:  Jasmine Rae Frost; Saba Shaikh; Alberto Severini
Journal:  Viruses       Date:  2022-06-18       Impact factor: 5.818

3.  One single-center serological survey on measles, rubella and mumps antibody levels of people in Youyang, China.

Authors:  Qing Wang; Xiaoping Cheng; Dandan Liu; Changhui Chen; Kaihu Yao
Journal:  Hum Vaccin Immunother       Date:  2021-10-08       Impact factor: 4.526

Review 4.  Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?

Authors:  Anna R Connell; Jeff Connell; T Ronan Leahy; Jaythoon Hassan
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.